FOLH1 and prostate carcinoma: Dietlein et al. reported comparable biodistributions for both tracers, but slightly higher sensitivity for 18F-DCFPyL compared to 68Ga-PSMA-11 (88% vs 66%) in patients with biochemically recurrent prostate cancer [29].